



March 31, 2014

TransEnterix, Inc. Files Pre-Submission Documentation with FDA Regarding its SurgiBot System

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery, today announced that it has completed a pre-submission filing with the U.S. Food and Drug Administration ("FDA") to request additional feedback from the FDA regarding its planned 510(k) filing for the SurgiBot™ system, pursuant to the FDA's Pre-Submission Program.

"Completing this pre-submission with the FDA on schedule demonstrates that our SurgiBot™ system development program continues to progress along our anticipated timeline," said Todd M. Pope, President and Chief Executive Officer of TransEnterix. "Our SurgiBot™ minimally invasive surgical robotic system, which will allow the surgeon to remain patient-side within the sterile field, represents a new approach in surgical robotics that we are excited to bring to market."

The pre-submission is consistent with FDA's "Guidance for Industry and Food and Drug Administration Staff," dated February 18, 2014. For additional information about this guidance, see

<http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM311176.pdf>

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery. The company is focused on the development and commercialization of the SurgiBot™ system, a minimally invasive surgical robotic system that allows the surgeon to be patient-side within the sterile field. For more information, visit the company's website at www.transenterix.com.

Forward-Looking Statements

This press release includes statements relating to the SurgiBot system and our current regulatory and commercialization plans for the system. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations and include whether we remain on track to complete the Company's 2014 Key Objectives, whether this pre-submission filing with the FDA demonstrates that our SurgiBot system will continue to meet our anticipated timeline, whether we can complete a financing in first half of 2014 and uplist to the NYSE MKT, and whether we will be able to bring the SurgiBot system to the market. Factors that could cause our results to differ materially from those described include, but are not limited to, whether the SurgiBot system's 510(k) application(s) will be cleared by the U.S. FDA, the pace of adoption of our product technology by surgeons, the outcome of coverage and reimbursement decisions by the government and third party payors, the success and market opportunity of our continuing and new product development efforts, including the SurgiBot system, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2013 and subsequent SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For TransEnterix, Inc.

Westwicke Partners
Mark Klausner, 443-213-0501
transenterix@westwicke.com

Source: TransEnterix, Inc.

News Provided by Acquire Media